ScreenerHero

TNG Transgene SA

EPA · FR · Healthcare · Biotechnology · transgene.com
0.7280EUR+4.00%Mkt Cap: 220.18M $P/E: —

Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II cl…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated - Common Stock
$127.85BUSDP/E 29.4
MRNA
Moderna, Inc. - Common Stock
$75.86BUSD
REGN
Regeneron Pharmaceuticals, Inc. - Common Stock
$75.69BUSDP/E 18.2
ARGX
argenx SE - American Depositary Shares
$57.51BUSDP/E 35.1
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc. - Common Stock
$44.29BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines Ltd. - American Depositary Shares
$40.51BUSDP/E 63.9
RPRX
Royalty Pharma plc - Class A Ordinary Shares
$33.03BUSDP/E 30.7
ALNY
Alnylam Pharmaceuticals, Inc. - Common Stock
$29.40BUSDP/E 38.3
ROIV
Roivant Sciences Ltd. - Common Shares
$25.80BUSD
BNTX
BioNTech SE - American Depositary Shares
$24.34BUSD
INSM
Insmed Incorporated - Common Stock
$24.27BUSD
INCY
Incyte Corporation - Common Stock
$23.37BUSDP/E 14.7
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
GMAB
Genmab A/S - American Depositary Shares
$21.69BUSDP/E 27.4
JAZZ
Jazz Pharmaceuticals plc - Ordinary Shares
$15.30BUSDP/E 16.1
ASND
Ascendis Pharma A/S - Ordinary Share
$14.99BUSDP/E 17.8
EXEL
Exelixis, Inc. - Common Stock
$14.47BUSDP/E 18.4
SMMT
Summit Therapeutics Inc. - Common Stock
$13.37BUSD

Key Statistics

Company
Market Cap220.18M USD
Enterprise Value100.16M USD
Revenue (TTM)6.11M USD
Gross Profit-30.73M USD
Net Income (TTM)-40.79M USD
Revenue/Share0.03 EUR
Last Price0.7280 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees145
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0005175080
Valuation
P/E (Trailing)—
P/E (Forward)-3.18
PEG3.08
EV/EBITDA-2.76
EV/Revenue16.38
P/S34.63
P/B1.67
EPS (TTM)-0.17
EPS (Forward)-0.22
52W Range
0.69204% of range1.500
52W High1.500 EUR
52W Low0.6920 EUR
Profitability
Gross Margin0.00%
Oper. Margin-559.30%
EBITDA Margin0.00%
Profit Margin-7657.96%
ROE-30.82%
ROA-27.03%
Growth
Revenue Growth-34.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-40.27M USD
CapEx (TTM)915.22K USD
FCF Margin-448.92%
FCF Yield-12.46%
Net Debt-98.55M USD
Net Debt/EBITDA2.71
Balance Sheet
Debt/Equity0.00
Current Ratio9.40
Quick Ratio8.83
Book Value/Sh0.42 EUR
Cash/Share0.36 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 EUR
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)1.100 EUR
Upside (mean)+51.1%
Target Range1.100 EUR – 1.100 EUR
# Analysts1
Ownership
Shares Out.278.26M
Float46.60M
Insiders80.78%
Institutions0.00%
Technical
SMA 500.7857 (-7.3%)
SMA 2000.8057 (-9.6%)
Beta—
S&P 52W Chg14.58%
Avg Vol (30d)134.99K
Avg Vol (10d)95.66K
Technical Indicators
RSI (14)24.0
MACD-0.0254
MACD Signal-0.0048
MACD Hist.-0.0206
BB Upper0.9616 EUR
BB Middle0.8237 EUR
BB Lower0.6858 EUR
BB Width33.48%
ATR (14)0.0209 EUR
Vol Ratio (20d)1.37x